Evidence map›Paper›PMID 42190838›Full record

ArticleBioorganic & medicinal chemistry letters2026

Disulfide bond formation between Cys22 and Cys44 in SARS-CoV-2 main protease.

Lauren R Blankenship, Kai Yang, Chia-Chuan Dean Cho, Yi-Ju Penny Chen, Banumathi Sankaran, Wenshe Ray Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lauren R BlankenshipTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Kai YangTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Chia-Chuan Dean ChoTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Yi-Ju Penny ChenTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77843, USA.
Banumathi SankaranMolecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Laurence Berkeley National Laboratory, Berkeley, CA 94720, United States.
Wenshe Ray LiuTexas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, TX 77843, USA; Department of Pharmaceutical Sciences, Irma Lerma College of Pharmacy, Texas A&M University, College Station, TX 77843, United States; Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, TX 77030, United States; Department of Biochemistry and Biophysics, College of Agriculture and Life Sciences, Texas A&M University, College Station, TX 77843, United States; Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, College Station, TX 77843, United States. Electronic address: wsliu2007@tamu.edu.

Funding

Use of the Noncanonical Amino Acid Mutagenesis Technique in Combination with Other Approaches to Study Functions of Posttranslational Lysine Modifications in ProteinsR35GM145351 · NIGMS · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2022 to 2026
$2.6M
A Multiplatform Approach to Develop ENL-Targeting Molecules as Drug Candidates for Acute Myeloid LeukemiaR01CA291968 · NCI · TEXAS A&M UNIVERSITY · PI Wenshe Ray Liu · 2024 to 2026
$2.4M
Development of fluorogenic and chemiluminogenic main protease substrates for cellular and in vivo imaging of SARS-CoV-2R21EB032983 · NIBIB · TEXAS A&M UNIVERSITY · PI LIU, WENSHE RAY · 2022 to 2023
$411k
NCI NIH HHS R01 CA291968NIBIB NIH HHS R21 EB032983NIGMS NIH HHS R35 GM145351
6 · The paper itself

Abstract

SARS-CoV-2 main protease (M

Indexed as

BetacoronavirusCoronavirus 3C ProteasesCysteineDisulfidesSARS-CoV-2Catalytic DomainCrystallography, X-RayHumansModels, MolecularOxidation-ReductionCoronavirus 3C ProteasesCysteineDisulfidesCovalent inhibitorsDisulfide bondMain proteaseRedox regulationSARS-CoV-2

Identifiers

PMID42190838
PMCPMC13577195

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.